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Tyrosinase antibodies recently have been reported to occur frequently in patients with vitiligo. We describe the detection of tyrosinase antibodies in vitiligo patients using in vitro 35 S-labeled human tyrosinase in a radioimmunoassay. Of 46 vitiligo sera examined in the assay, five (10.9%) were found to be positive for tyrosinase antibodies . In contrast, 20 control sera and sera from 10 patients with Hashimoto's thyroiditis were negative . Four of the sera positive in the radioimmunoassay were also positive in an ELISA using mushroom tyrosinase as antigen. Absorption studies indicated that pre-incubation ~ith mushroom tyrosinase absorbed out the immunoreactivity of the positive sera in the radioimmunoassay, suggesting cross-reactivity, but this absorption was never complete, indicating that there are tyrosinase antibodies in human sera that do not react with the V itiligo is a commo n skin di sorde r, the precise eti o logy of w hich remains o bscure . Som e studies have sh own that an ti-me lanocyte autoantibodies are often present in the se ra of vitiligo pati ents (C ui et a/, 1992) and th at the re is a correla tion be tween the presence and le vel of these antibo di es and the ex te nt (Naughto n cl a/ , 1986) and activi ty (Haming et a/, 1991) of v itiligo. T hese observations and the fac t th at the se an. tibo dies can kill human m elanocytes ;, vitro (Norris et a/, 1988) su ggest they may be in volved in the pathogenesis of vitili go, although it is also p. o ss ible tha t antibod y produ ction may m ere ly refl ect a secondary immunolo gic response to m elanocytes damaged by o ther m echanism s. R ecent w o rk has tri ed to identi f:)r th e m elan ocyte autoariti ge ns again st which vitiUgo antibo di es react. Some o f th e an tigens are unique to pigm ented cells, w hereas o thers are also expressed on nonpig m ented cells, and all appea r to be located on the cell sm·face (C ui el a/, 1992). Tyrosinase, a key en zy m e iu volved in m e lanin synthesis, has been implica ted as an au toantige n in two studies (Song el a/, 1994; B aharav et a/, 1996) , but others have dismisse d mushroom protein. There was no obvious association between the presence of tyrosinase antibodie s and the age of the patients (range: 22-62 y), their duration of disease (range: 5-20 y), or the type of vitiligo (one segmental, one symmetrical/periorificial, three symmetrical), although the three patients with the highest antibody levels also had an associated autoimmune disorder (one with Graves' disease; two with autoimmune hypothyroidism). The results confirm that tyrosinase autoantibodies are present in the sera of vitiligo patients but at a low frequency. The technique described is se nsitive and quantitative a nd allows the detection of confor1national epitopes. I t will be useful in longitudinal stu4ies to determine the relation between the clinical features of vitiligo and tyrosinase antibody levels. K ey wor•d: autoimuuurity. J ln11est Demra.tol 109:69-73, 1997 an y role. ' T h e curren t stud y aime d to analyze vitiligo sera for the presen ce of tyrosinase an tibo dies using a novel radi oimm unoassay (lU A) ·with 35 S-labeled recombinan t human tyrosinase. T his type of assay recentl y has been widely used , for example, to detect antibodi es against glutamic acid d ecarbo:..-ylase, steroid 21 -hydroxylase, and ca ndida! antigen s in insulin-dependen t diabetes m e llitus, Addison' s disease, and autoimmune polyglandular syndro m e type 1, respectively (Falorni el a/ , 1 994, 199 5; Pe terson el a/, 1996) .
MATERJ A LS AND M ETH O D S
Patients Sera fro m 46 seq u e n~ial patients with vitiligo (14 m eu , 32 wom en ; m ean age 48 y, range 23-79 y) co l.l ected in derm atology and en doc rin o logy clinics between J anu ary ·t 990 and September 1996 were used. Pati ents were characterized with respect to th e presence of associated auto immun e d iseases: 20 had no other d isease and n o fa mily hi story of autoi mmune disease; nin e h ad n o oth er disease bur h ad a f.1mil y histo ry of auto irn1n une disease; 1 7 h ad an au toi n1n1unc d isord e r . A u toin1 n1unc diseases w ere: G raves' disease, 4; autoimmun e h ypo thyro idism , 9; al opecia, 2; Add ison' s di sease with hy pothyro idism and type 1 d iabetes m elli tus, 1; and pernicio us ane mia w ith hypo thyro idism , 1.
Sera from 20 hea lthy labo ratory personnel (eight m en , 12 wom e n ; age range 25-43 y, m ean 33 y) w ere used as co ntml s. As a further set of co ntrol s, 10 sera fro m patien ts (two m en , e ight wom en ; age ran ge 34 -73 y. m ean 48 y) with H ashimo to's th yro idi tis bu t wi th o u t vitiligo were tested .
A ll ser a were kept froze n atzo•c. T he stud)' was ap proved by th e ' X ie Z, B ysuynJ C: An ti-tyrosinase an ti bodies in vitiligo. ) l twest Dcr111 at"l 106 : 938, 1996 (abstr) . 0022-202X/97 /S I 0.50 • Co pyright © 199 7 by T he Society fo r In vestigative D erm atology. In c.
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Ethics Committee of the Northern Genera l Hospital, Sheffield, and all subjects gave informed consent.
Rabbit Antisera Rabbit polyclonal antisera aPEP7 (Tsukamoto et a/, 1992) , generated against a synthetic peptide that corresponds to the carboxyl terminus of mouse tyrosinase, and aPEP8 (Tsukmnoto et 0 /, 1992), generated against a synthetic peptide that corresponds to the carboxyl terminus of mouse tyrosinase-related protein 2 (TRP2), were a gift of Prof. Vincent Hea6ng (National Institutes of Health, Bethesda, MD). · Cloning of Human Tyrosinase eDNA into pBluescr~pt A fl'lllength human tyrosinase eDNA fragment in pRHOHT2 (Takeda et a/, 1989) was a gift of Prof. Slugeki Slubahara (Tohoku University School of Medicine, Sendai, Japan). initially, the eDNA was subcloned into pBiuescript SK (Stratagene, La Jolla, CA) to allow in 11itro transcription-translation of tyrosinase under control of the T7 promoter. · Plasmid plU-lOHT2 (1 f.Lg) was cleaved with enzymes Xbal. and Sail (Promega, Southampton, U.K.) in a 50-f.LI reaction volume with buffer containing 6 mM Tris HCl (pH 7.9), 6 mM MgCl 2 , and 150 mM N~Cl at 3 7°C for 90 miJl. The fragments generated were resolved on a 1% low-melting-point agarose gel (Sambrook eta/, 1989) , and the 2-kb DNA band contau~ing tyrosinase eDNA was excised and purified using a Wizard DNA clean-up system (Promega). Xbal-Sa/I-restricted pBluescript SK (2.96 kb) was prepared in the same way. Ligations were cond ucted overnight at Hi°C in a 15-/l,l reaction mixture with 1 U ofT4 DNA lig'lse (Promega), 50 ng of restricted pBluescript SK, 100 ng of tyrosinase eDNA, and buffer containing 66 mM Tris HCl (pH 7.6), 6 mM MgCI 2 , 1 mM dithiothreitol, and 66 f.LM ATP. A 2-f.Ll aliquot of the ligation mixture was used to trm1sfonn 100 f.LI of competent Eschelichin coli XL1Blue (Sambrook et al, 1989) . Transformed cells were selected on LB agar (Sambrook et. a/, 1989) containing 50 }Lg ampicillin per ml. Plasmid was prepared from 10 transformants using a Wizard miniprep DNA purification system (Promega). After restriction with Xbnl and Sn/1, each plasmid was analyzed by agarose gel electroph oresis (Sambrook et nl, 1989) to identify those carrying a DNA insert. One appropriate recombinant plasmid was designated pBSTYR. The construct was verified by dideoxy sequencing using a Seque~ase version 2.0 IGt (Amersham, Aylesbury, U.K.) with [a-3 5 SjdATP (Amersham) and T7 primer (Prom ega) . Large-scale preparation of pBSTYR was done using the Wizard midiprep DNA purification system.
In Vitro Coupled Transcription-Translation of Human Tyrosinase Full-length human tyrosinase was produced ;, 11itro from the eDNA in pBSTYR using a TnT T7-coupled reticulocyte lysate system (Promega). Plasmid DNA (2 J.Lg) was incubated for 120 ruin at 30°C in 50 J.Ll reaction mixture containing 25 f.LI rabbit reticulocyte lysate, 1 f.Ll T7 TnT RNA polymerase, 1 f.Ll ami11o acids minus methionine, 40 U RNasin (Promega), 2 f.LI TnT reaction buffer, ru1d 4 f.LI translation-grade [ 35 S]methiouiJ1e (1000 Ci/mmol, 1.0 mCi per ml; Amersham). The reaction was stored at -20oc until needed. · To determine the percentage incorporation of[· 15 S]methionine, we added 2 f.Ll of the reaction mixture to 98 f.Ll of1 M NaOH/2% H 2 0 2 and incubated it at 37°C for 10 min. After tins, 900 f.Ll of ice-cold 25% trichloroacetic acid (TCA)/2% casamino acids (Difco, Detroit, Ml) was added, and the reaction was incubated o n ice for 30 miJ1. To collect the precipitated translation products, 250 J.LI of the TCA reaction mix was vacuum filtered onto a Whatman GF/ A glass fiber filter prewetted with cold 5% TCA. The filter was ru1sed tluee times with 1 ml of ice-cold 5% TCA and once with 1 ml of acetone and then allowed to dry at room temperature before counting in a11 Lilli 1217 Rackbeta liquid scintillation counter. To determine tota. l counts per nlli1 (cpm) present u1 the reaction, a 5-f.Ll aliquot of the TCA reaction mix was spotted directly onto a filter. T ins was dried for 10 miJ1 before countiJ1g. The percent incorporation of [ 35 S]metluonine was deternuned as (cpm of washed filter/cpm of unwashed filter X 50) X 100.
Electrophoretic Analysis and Autoradiography Sodium dodecyl sulfute-polyacrylamide gel electrophoresis (SDS-PAGE; Sambrook eta /, 1989) of i11 11itro translated products was performed in a 10% polyacrylamide resolving gel containing 325 mM Tris HCI (pH 8.8) and 0.1% SDS and a 4'!fo polyacrylamide stac!Gng gel containing 125 mM Tris HCI (pH 6.8) and 0.1 % SDS. The gel running buffer contained 25 mM Tris HCI (pH 8.3), 192 mM glycuJC, and 0.1% SDS.
A 5-J.LI aliquot of tl1e in uitro translation reaction mixture was added to 20 f.LI of SDS sample buffer containing 63 mM Tris HCI (pH 6.8), 10% glycerol, 2% SDS, 5% 2-mercaptoethanol, and 0.001% bromophenol blue and heated to 1 00°C for 2 min before loading a 10-f.LI sample. To visualize protein markers, the gel was stained with O.oso;., Coomassie blue in 10% glacial acetic acid /25% isopropanol and destained with l 0% glacial acetic acid/25% isopropanol, each for 30 min at room te,;1peratqre. The gel was then soaked u1 AmplifY scintillant (Amersham) for 30 min at room TI-lE JOURNAL OF INVESTIGATIVE DERMATOLOGY temperature before drying at 80°C for 2 h on 3 MM filter paper under vacuum. Autoradiography was carried out at -70°C using x-ray film (Genetic Research Instrumentation Ltd, Essex, U.K.). Protein molecular weight standards (Sigma, Dorset, U.K.) consisted of myosin (205 kDa), J3-galactosidase (116 kDa), phosphorylase b (97 kDa), serum albumin (66 kDa), oval bumin (45 kDa), carbonic anhydrase (29 kDa), and soybean trypsin inhibitor (20.1 kDa). · RIA for Tyrosinase Antibodies For each assay, an aliquot of the ill 11itro tianslation reaction mixture (equivalent to 15,000-20,000 cpm of TCA precipitable material) was suspended in 50 f.Ll immunoprecipitation buffer contaiJ1ing 20 mM Tris HCI (pH 8.0), 150 mM NaCl, 1% Triton X100, and 10 mg aprotinin per ml. Serum was then added to a fmal dilution of 1:1.0 unless stated otherwise. After incubation overnight witl1 shaking at 4 °C, 50 f.Ll of proteiJJ G Sepharose 4 fast Flow slnrry (Pharmacia Biotech, Uppsala, Sweden), prepared according to the manufacturer, was added and incubated for 1 h at 4°C. T he protein 0 Scpharosc-antibody complexes were then collected by centrifugation and W<lshed six times for 15 min in immunoprecipitation buffer at 4°C. Immtmoprecipitated radioactivity was eva luated in a liquid scintillation analyzer. Three aliquots of each sample were counted and the mean cpm calcula~ed. The SD oftl1e mean was always witlu11 12'Yo. For analysis by SDS-PAGE, the protein G Sepharose-antibody complexes were resuspended in 100 f.LI SDS sample bulfer, boiled, aud centrifuged, and the supematant was recovered for electrophoresis.
For absorption studies, each positive patient serum at a final dilution of 1:10 was incubated with either 1 f.Lg, 5 }Lg, 10 f.Lg, 20 f.Lg, or 50 ~g of musluoom tyrosinase (Sigma) in 50 f.Ll ofimmunoprecipitation buffer for 2 h at 4°C. Bovine serum albumin (Sigma) was used as a control in the same amounts. After pre-incubation, 3 5 S-tyrosit1ase was added as above, and the lUA was performed as described.
Enzyme-Linked Immunosorbent Assay (ELISA) for Tyrosinase Antibodies Tins was performed essentially as described elsewhere (Bah arav et a /, 1996) . Coming polystyrene 96-well microtiter plates (Bibby Sterilin Ltd, Mid Glamorgan, U.K.) were coated with 100 f.Ll of mushroom tyrosinase at a concentration of 50 f.Lg per ml in buffer contaiJllil g 1.5 mM Na 2 C0 3 , 3 .5 mM NaHC0 3 , and 3.0 m.M NaN 3 (pH 9.2) and incubated oven-right at 4°C. The plates were then washed six times with phosphatebuffered saline contaiJ1ing 137 mM NaCI, 2. 7 mM KCI, 10.1 mM Na 2 HP0 4 , 1.8 mM l<H 2 P0 4 (pH 7.4), and Tween-20 at 0 .05% (PBS/ Tween) and then blocked with 0.5% gelatin in PBS at room temperature for 1 h. After wasllli1g six times with PBS/Tween, 100 f.L] of each serum, diluted 1:50 in PBS/Tween, was added to a well and the plates were incubated at 37°C for 2 h . T h e plates were washed six times with PBS/Tween and then 100 f.Ll of anti-human lgG (It-chain speciftc) alkaliJJe phosphatase conjugate (Sigma), diluted 1:1000 in PBS/Tween, was added for 2 h at room temperature. After washing six times in PBS/Tween, 100 f.Ll of Sigma 104 phosphatase substrate (Sigma) was applied to each well at a concentration of 1 rng per ml u1 buffer contaiJllilg 11.9 mM Na 2 C0 3 , 16 mM NaHC0 3 , and 2 .1 mM MgCI 2 (pH 9.3). A LabSystems Integrated E TA Management System (Life Sciences International , Hampshire, U .K.) was used to read absorption at 405 nm. In each assay, sera were tested in duplicate and the average value was taken.
Expression of Tyrosinase Antibody Levels To contro l for interassay variation, we expressed tyrosin ase antibody levels as a relative index (TyrAb index). A TyrAb index for each serum tested in the RIA was calculated as cpm in1munoprecipitated by tested serw11/mea n cpm in"lmunoprecipitatcd by the 20 healthy controls. Each senun was tested in at least three experiments, m1d the mean TyrAb index was calculated from these. The SD of the mean was aiways within 12%. The upper level of normal for the assay was calculated using tl1e mean TyrAb index + 3 SD of a population of 20 healthy individ uals.
For rl1e ELl SA, rl1e TyrAb u1dex for eacll serum sample tested was ca.lcu.la ted as absorbm1ce at 405 nm for tl1e tested serwn/mean absorbance at 405 nm for 20 healthy controls. Each serum was tested in at least tlu-ee e>.]Jeciments, and tl1e mean TyrAb index was calculated from these. T he SD of the mean was always witllli1lO%. The upper level of norma] for the assay was calculated using the mean TyrAb i)ldex + 3 SD of a population of 20 heald1y controls. The inununoreactivity of 35 S-tyrosinase \.vas tested usin g two rabbit polyclonal sera: tyrosinasc-spcciftc aPEP7 and T RP2-specific a PEPB. These sera were in cu bated at a dilu6 on of 1: l 00 with <Jn aliquot of the in viiro trans lation reaction mixture before incubati on with protein G Scpharose as described in Ma terials nnd r\lferilorls. Th.c protein G Sepharose-antibody co mpl exes were resuspended in l 00 iLl ofSDS sample buffer and boiled, and the sup ernatant was recovered for analysis by SDS-PAGE. Lane '/, in vitro tran slated 35 S-tyrosinase; lane 2, 35 5-tyrosi.nasc immunoprecipitatcd with tyrosillase-spec ifi c a PEP7 antiserum; /nn e 3, 35 5-tyrosinase immunoprecipitated with TR..P2-speciftc tYPEP8 antiserum.
RESULTS
pred icted from the amino acid sequ e n ce of the protein (Takeda ef a/, 1989). The immunoreactivity of the i11 11itro translated recombinant human tyrosinase was tested u sing rabbit antise ra at a 1:100 dilution . 35 S-tyrosinase was immun oprecipitate d by the tyrosinasespecifi c aPEP7 anti. serurn but not by the TRP2-spccific aPEPS antiserum (Fig 1) . The average p e rcentage of 35 S-tyrosinase imrnunoprecipitated in four assays by the cYPEP7 antiserum was 65 :!:: 10% (mean :!:: SD) at a dilution ofl:IOO. To test the se n sitivity of the IUA, we immunopreci pitated 35 S-tyrosinase with serial dilutions of the aPEP7 antiserum. Fro m thjs, the end point dilution of the antiserum was 1:18,000.
RIA of Vitiligo and of Healthy Control Sera Sera from 46 vjtiligo patients and 20 h ealthy controls, at a dilution of 1:10, were tested for their ability to immunoprecipitate 35 S-tyrosinase . For each se rum, a TyrAb index was assigned as the m e an TyrAB index of at least three exp e riments with an SD of less than 12'!/o. The upper leve l of normal for the lUA (mea n TyrAb index + 3 SD of 20 hea lthy controls) was es timated as a TyrAb index of1.27 (Fig 2) . Non e of tbe h ealthy indiv iduals was positive for tyrosinase antibodies. Among 46 vitiligo patients, five (10.9%,) had a TyrAb index above 1 .27 (Fig 2) and were co n sidered positive for tyrosinase antibodies. Sera from 10 patients with Hashimoto's thyroiditis had a 1u e an Ty rAb index of0.96:!:: 0.10 (mean :!:: SD), and a1! 10 were n egative for antibodi es to tyrosinase. SDS-PAGE was use d to ch eck that the radioa ctivity immunoprec ipitated b y eac h of the positive sera was du e to 35 S-tyrosi.nase. Figure 3 indicates that the fiv e positive sera immunoprecipitated a band of the corre c t size when co mpared with that precipitate d b y tyrosinase-specific a PEP7 antiserum .
T he three most strongly reacting se ra were analyzed at dilferent dilutions in the RIA along with a group of six h ealthy co ntrols. A TyrAb index for each dilution was calculated and plotted as a tl.mction of se wm dilution (Fig 4) . For these three sera , saturated bindin g was observed at dilutions up to 1:100 .
ELISA of Vitiligo and of Healthy Sera Using Mushroom Tyrosinase Sera from 46 vitiligo patients and 20 healthy individuals were tested in the ELISA with mushroom tyrosinase. For each sample, a TyrAb index was calc ulated as the mean TyrA b index of at least three experiments with an SD of less than 1 0%. The upp e r level ofnonmtl tor the E LlSA (mean TyrA b index+ 3 SD of20 h ea lthy controls) was estimate d as a TyrAb index of1.96 ( Fig 5) .
All the controls were n egative . Of the 46 v itiligo patients, fo ur (8.7°/c,) had an antibody index greater than 1.96 and were considered positi ve for tyrosinase antibodies. These four were a lso positive b y the RIA , and the ranking of their reactivity was the same in both assays. Patients with Hashimoto 's thyroiditis had a m ean TyrAb index of 0.74 :!:: 0.22 (mean :!:: SD), a.nd a.l.l 1.0 se ra were negative.
Absorption Studies To d ete nuin e whether th e immunoreactivity of sera in the ELlS A and in the JU A was ide nti ca l, we performed absorption studies as described in Materials a11d l\lfer/r ods using th e kD 97-66-45 -2 3 4 5 6 7 8 9 10 Figure 3 . SDS-PAGE of 35 S-tyrosinasc i.mmunoprecipitated witlt either vitiligo or healthy scruut. Se ra were incubated at a dilution of 1:10, except for aPE P7 , which was used at 1:100, with an aliquot of the i11 11itro translation reaction mixtm·e before iJlcub ation with protein G Sepharose as described in Ma terials n11rl Met/10ds. T he protein G Sepha.roscantibody complexes were resuspended in I 00 fLI of SDS samp le btdfcr aud boiled, and the supernatan t was recovered for anal ysis by SDS-PAGE. Lane 1, 3 5 S-tyrosinase .immuuoprecipitated with a P.EP7 antiserum; lanes 2-6, 35 5-tyrosinase imnmnoprecipitated with positive vitili go se ra ; ln11 es 7-8, 35 S-tyrosinase immunoprecipitated with negative vitili go sera; la11cs 9-10, 3 5 S-tyrosinase immunop recipitatcd with healthy co ntrol sera.
4 -·--···-····-·--··--·-·-··----·--·····----- three most pos1tJ.ve sera. Figure 6 shows the percentage cpm immunoprecipitated by each serum in the RIA a fter pre-incubation with varying amow1ts of either mu shroom tyrosinase or bovine serum albumin. The results indicate that the mushroom tyrosinase was able to absorb out the immunoreac tivity of these sera in the RIA. T lus was neve r complete, howeve r; there was 58-72% loss of reactivity with the highest amount of mushroom tyrosinase used . Bovine serum albumin at similar concentrations had no eftect on tyrosinase binding in the RIA. It was possible tha t proteolytic activity in the mushroom tyrosinase extract was degrading the labele d protein during incubation and thereby causing a d ecrease in cpm in the RIA. To test tlus, w e incubated ~5 5-tyrosinase overnight with either 20 fLg or 50 /Lg of mushroom tyrosinase and then analyzed the samples by SDS-PAGE and autoradiography. D e gradation of 35 5 -tyrosinase was not detected by this analysis.
DISCUSSION
Tyrosinase antibodies have been detected in the sera of p atie nts with vitiligo in two previous studies (Song eta/, 1994; Baharav et al, 1996) , implicating the e nzyme tyrosinase as an autoantigen. The first study u sed bacte rially synthesized human tyrosinase and im-munoblotti11g (Song et al, 1994) , wluch is a relatively insensitive technique and d e tects linea r epitopes that are unlikely to be as important as conformational epitopes in the pathogenesis of autoilnmune disease . The second study use d mush.room tyrosinase in an ELISA (Baharav el al, 1996) . Although this m e thod is sensitive and allows the d etection of conformational epitopes, the u se of mushroom tyrosinase is UJ1ukely to allow the detection of aJJ epitopes present on the human protein. ln contrast to these two studies, others have reported the absence of tyrosina se antibodies in all vitiligo sera examined by immunoblotting (n = 40), immunoprecipitation (n == 20), and ELISA (n = 13) using human melano cyt e extract as a source of tyrosinase. 2 Recendy, RIAs have been develope d to d e tect specific antibodies in the sera of patie nts with autoimmune di sease (falorni et a/, 1994 , 1995 Peterson et a/, 1996) . These involve in vitro translation 2 Xie Z, BystrynJC: Anti-tyrosinase antibodi es in vitiligo.] !lwest Dermntol 106:938, 1996 (abstr). and concomitant radiolabeling of the antigen of interest. T he method combines sensitivity with the possibility of detecting conformational epitopes. It also allows quantitative m e asurement of the level of antibodies and avoids the n eed to exp ress and purify the protein of interest from either bacterial or m ammalian cells. For these reasons, we have developed an RJA for the detection of tyrosinase antibodies. Using coupled in 11itro transcription-translation, w e were able to produce 35 S-Iabeled recombinant human tyrosi11ase. T lus was of high quality as evaluated by SDS-PAGE, and contanunation by lower-molecular-weight products was nll.rumal. The protein was also immunoreactive and could be im.munoprecipitated by specific anti-tyrosil1ase antiserum.
T he technique was used to examine vitiligo and control sera for tyrosinase antibodies. Healthy control sera and sera from patients with Hashimoto's thyroiditis did no t contai11 tyrosinase antibodies.
Among 46 v itiligo sera tested, five (10.9%) contained tyrosinase antibodies. This was a much lower frequency than found in the study of S~p.g et a/ (19~4), in wluch 61% · of vitiligo pati ents had tyrosinase antibodies. T here are sev~ral poss ible explanations for this discrepancy. The use of immw10blott~ng in the psevious report is a m~or difference fro' m our study, and no quantitative data' were provided to validate the definition .of positivity. The differences may also reflect variations in d1e groups of patients studied , such as race and geographic loca tion. In addition, all of the p atients in the study of Song et nl (1994) had a personal or family history of autoinmnme disease, but even considering the 26 sinillar patients in the present stud y, only 3 (11.5 %) had tyrosinase antibodies.
The state of the disease may also affect the frequency of positive sera. In patients with active vitiligo, melaJlocy tes are still being destroyed, and sera are therefore more likely to have antibodies to m elanocyte antigens (Harnmg et al, 1991) , although formation of immune complexes could theoretically reduce d etectability. When the disease is inactive, tyrosinase ru1tibodies may decrease to undetectable levels. It is difficult, however, to assess the activity of vitiligo at a single clliuc visit, and there are no reliable serologic markers for activity. These findings suggest that it m ay be word1 a prospective study to explore the value of tyrosinase antibody levels in this ca pacity. Finally, it is possible that so m e epitopes are not present on the tyrosrnase used in tl:lls assay, as it m ay not be properly glycosylated in the in 11itro transcription-translation system. T his could account for the low frequ ency of tyrosinase antibody-positive sera. The tyro sinase used in the study of Song eta/ (1994) , however, was produced in bacteria and would therefore not be glycosylated or processed, as it would be in the melanocyte; yet, still a lugh frequency of tyrosinase antibody-positive sera was found.
Fou1· of the patients positive i11 the R.IA were also positive for tyrosinase antibodies in the ELISA using mushroom tyrosinase. T lus may have been due to mtibodies reacting w ith a conformational epitope, as the amilw acid homology between mushroom and human tyrosinase is low: the region of highest homo logy between the two proteins occurred i11 a 111-ami no acid overlap, where 39.6% sinularity and 23.4% identity w ere found. Incomplete absorption of antibodies by mushroom tyrosinase ( Fig 6) indica ted that there may be tyrosinase antibodies in human sera that do not react with the mushroom protein, and tlu s could account for the negative result i11 one patient in the ELISA. TYROSINASE ANTJl30DlES rN VJT lLJGO 73 T he presence of tyrosi nase antibodies in five patients was not associated with age (range: 22-62 y), disease duration (range: 5-20 y), or the type of vitiligo (one segm e ntal ; one symm etrical / pet;orificial; tl1ree symm etrical). With respect to autoimmune disorders, the two positive patients with the lowest levels of tyrosinase antibodies had no personal or fa mily lustory of associated autoimmune di seases. T he three patients with the highest levels had an associated autoimmune disorder: Graves' disease in one and autoimmune hypoth yroidism in two .
We h ave developed a sensitive, quantitative RlA for tyrosinase antibodies based o n radiolabele d human tyr:osi.nase p roduced in an iu IJitro transcriptiontranslation sys tem. ln contras t to a recent report testing vitiligo sera for tyrosinase antibodies by immunoblot-tll1g (Song et a/, 1994) , the prevalence of tyrosinase an tibodies it~ our patients with vitiligo was low (1 0. 9%) and was not confined to those with an associated autoimmune disease. T lus RlA should be usefnl in clarifying the rol e of tyrosinase antibodies in the pathogen esis of vitiligo.
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